A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-20 DOI:10.1080/2162402x.2023.2290787

Chia-Chi Lin, Elena Garralda, P. Schöffski, David S. Hong, L.L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, B. Ma, C. Kyi, Daniel SW Tan, P. Cassier, J. Sarantopoulos, A.J. Weickhardt, Richard D. Carvajal, Jennifer Spratlin, T. Esaki, F. Rolland, Wallace Akerley, B. Deschler-Baier, L. Rispoli, T. Samant, Niladri Roy Chowdhury, D. Gusenleitner, Eunice L. Kwak, V. Askoxylakis, Filippo G. de Braud

引用次数: 0

查看原文本刊更多论文

一项针对晚期实体恶性肿瘤患者的抗 LAG-3 依拉米单抗联合抗 PD-1 斯帕妥珠单抗的 2 期、多中心、开放标签研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.